DiaSorin, a biotechnology company, has received all the marketing approvals for hepatitis, retroviral and syphilis assays on its Liaison XL platform for the Chinese market. DiaSorin is now entering the hepatitis B, hepatitis C and ...
Tags: DiaSorin, HCV, HIV, pre-surgical screening testing
Each week, KHN compiles a selection of recently released health policy studies and briefs. Journal of the American Geriatrics Society: Hospitalization Of Elderly Medicaid Long-Term Care Users Who Transition From Nursing Homes To compare ...
Each week, KHN compiles a selection of recently released health policy studies and briefs. Journal of the American Geriatrics Society: Hospitalization Of Elderly Medicaid Long-Term Care Users Who Transition From Nursing Homes To compare ...
Hepatitis C treatment isn't pretty, but the dark days of weekly injections, rough side effects and no guarantee of full recovery from the liver-damaging disease may soon be over, researchers report. Two studies, both published in the Jan. ...
A survey of opioid treatment programs finds that the proportion offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) declined substantially between 2000 and 2011, despite guidelines ...
Tags: opioid treatment programs, human immunodeficiency virus
Sovaldi (sofosbuvir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with Hepatitis C. It's considered a breakthrough medication since it's the first such drug that does not require same-time ...
Tags: Sovaldi, chronic infection, Hepatitis C
The U.S. Food and Drug Administration approved Sovaldi -- sofosbuvir -- to treat chronic hepatitis C virus infection without interferon, officials say. Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center ...
Tags: FDA, Sovaldi, sofosbuvir, chronic hepatitis C, health
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) 400mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection ...
Tags: Gilead Sciences, Chronic Hepatitis
The US Food and Drug Administration (FDA) has granted orphan drug designation to Conatus Pharmaceuticals' drug candidate emricasan for the treatment of liver transplant patients with reestablished fibrosis to delay the progression to ...
US-based Biozone Pharmaceuticals has announced that it has agreed to terms and signed a letter of intent (LOI) to merge with Cocrystal Discovery, a privately-held biotechnology company developing antiviral therapeutics for human diseases. ...
The US Food and Drug Administration (FDA) has approved Janssen Therapeutics' NS3/4A protease inhibitor 'Olysio (simeprevir)' for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with ...
The US FDA's Antiviral Drugs Advisory Committee has recommended approval for Medivir's investigational protease inhibitor simeprevir (TMC435) 150mg capsules for the treatment of genotype 1 chronic hepatitis C in adult patients with ...
Tags: Medivir, Hepatitis C Patients
US-based pharmaceutical firm Merck has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its investigational oral combination regimen MK-5172/MK-8742 for the treatment of chronic hepatitis C virus ...
Abbott has introduced FDA-approved hepatitis C virus (HCV) genotyping test for patients in the US. The completely automated RealTime HCV Genotype II test determines the specific type or strain of the HCV virus present in the blood of an ...
Tags: US, Health&Medicine, Abbott
Laboratory Corporation of America Holdings (LabCorp) has become the first clinical reference laboratory to offer Roche COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0, a viral load assay for hepatitis C virus. Designed with enhanced ...